Form 10-Q Compass Therapeutics, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Compass Therapeutics (CMPX) PT Lowered to $7 at Jefferies
May 13, 2024 1:21 PM EDTJefferies analyst Maury Raycroft lowered the price target on Compass Therapeutics (NASDAQ: CMPX) to $7.00 (from $8.00) while maintaining a Buy rating.
The analyst comments "CMPX updated pivotal BTC ph.II/III data guidance to 1Q25 (vs YE24), which we think is incremental given that enrollment... More
